In order to further improve the diagnosis and treatment level of type 2 inflammatory skin diseases, the National Clinical Center for Skin and Immune Diseases established a standardized diagnosis and treatment center for type 2 inflammatory skin diseases to systematically and effectively understand the current treatment status of patients with type 2 inflammatory skin diseases, as well as the efficacy and safety of various treatment methods during practices, so as to further improve the diagnosis and treatment level of type 2 inflammatory skin diseases and help patients with type 2 inflammatory skin diseases.
Study Type
OBSERVATIONAL
Enrollment
100,000
Peking University First Hospital
Beijing, China
RECRUITINGDemographics
Age, sex, ethnicity, body weight and height
Time frame: baseline
Age at Type 2 skin disease onset
Age of study patients at time of Type 2 skin disease onset
Time frame: baseline
Type of current Type 2 skin disease therapy
Type of therapy administered to treat Type 2 skin disease (e.g., systemic, topical, other)
Time frame: Baseline
Presence of Type 2 skin disease and selected comorbid conditions
Percentage of patients with Type 2 skin disease and selected comorbidities (e.g., asthma and allergic rhinitis) at baseline and during study
Time frame: Baseline to Month 120
Percentage of patients using specific Type 2 skin disease therapies and initiating new therapies
Percentage of patients using specific Type 2 skin disease therapies and initiating new therapies
Time frame: Baseline to Month 120
Eczema Area and Severity Index (EASI)
EASI score as assessed by physician
Time frame: Baseline to Month 120
Body Surface Area (BSA) percentage affected by Type 2 skin disease
BSA score as assessed by physician
Time frame: Baseline to Month 120
Patient Oriented Eczema Measure (POEM) questionnaire
POEM score as reported by the participant's caregiver
Time frame: Baseline to Month 120
Dermatology Life Quality Index
DLQI score as reported by the patients or caregivers
Time frame: Baseline to Month 120
Bullous Pemphigoid Disease Area Index(BPDAI)
BPDAI score as assessed by physician
Time frame: Baseline to Month 120
Autoimmune Bullous Skin Disorder Intensity Score (ABSIS)
ABSIS score as assessed by physician
Time frame: Baseline to Month 120
Chronic Urticaria Quality of Life questionnaire (CU-Q2oL)
CU-Q2oL score as assessed by patients or caregivers
Time frame: Baseline to Month 120
Urticaria Activity Score 7a （UAS7a）
UAS7a score as assessed by physician
Time frame: Baseline to Month 120
Urticaria Control test (UCT)
UCT score as assessed by patients or caregivers
Time frame: Baseline to Month 120
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.